01:58:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 Ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Kvartalsrapport 2019-Q1
2018-09-24 Årsstämma 2019
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Kvartalsrapport 2018-Q1
2017-09-25 Årsstämma 2018
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamma inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2022-02-18 16:44:58

Mölndal, Sweden, February 18, 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that Erie County Medical Center in Buffalo, New York, USA, has completed treatment of their first two patients with the OPRA[TM] Implant System, making it the first hospital in the state to perform surgeries with Integrum's implant system. In parallel, Integrum will collaborate with Garwood Medical Devices, and researchers at the University at Buffalo, to develop the infection control system BioPrax.

Integrum develops and markets OPRA­­[TM] - the only FDA approved bone-anchored treatment system for major limb loss. The use of OPRA[TM] is supported by a substantial body of scientific and clinical literature showing that the system significantly improves functional outcomes, and quality of life, in individuals who have suffered limb loss.

Integrum is working to train and support clinical teams at selected key hospitals in the US, in order spread awareness of the OPRA[TM ]system. The collaboration with Erie County Medical Center's (ECMC) marks an important step forward, as Integrum continues to expand its presence in the US market. ECMC, with Integrum's support, fully completed treatment of their first two patients over a six-month period.

Integrum is also working with Garwood Medical Devices, a Buffalo based medical device company developing the microelectronic system BioPrax to mitigate implant-related infection. Integrum is continuously evaluating technologies to effectively decrease infection rates since it can help expand the use of OPRA[TM] to patients more prone to infections, such as those with certain comorbidities and the elderly. In June 2021, Integrum and Garwood Medical Devices entered a memorandum of understanding to explore a collaboration aimed at expanding treatment indications for the OPRA[TM] Implant System. Garwood Medical and the affiliated research team at the University at Buffalo were recently awarded a $744,000 grant from the US Department of Defense (DoD) to investigate if the BioPrax system can be used to mitigate implant-related infection. The collaboration was recently featured in a news article in Buffalo News (https://buffalonews.com/news/local/an-experimental-medical-device-built-in-buffalo-already-is-paying-dividends/article_20dc6ba4-3dd6-11ec-84b2-2f46cd75ea66.html#tracking-source=home-top-story-1).

"We are pleased to work with the skilled surgical and rehab team at the ECMC to successfully facilitate incorporation of the OPRA[TM] implant system in their treatment offering to patients who have suffered major limb loss. We are further looking forward to collaborating with Garwood Medical Devices and hopefully find a better solution to address infection and alleviate patient suffering", said Tom Dugan, President, Integrum Inc.